Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK9 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
CDK9 siRNA is a research-grade synthetic small interfering RNA (siRNA) designed to silence the expression of cyclin-dependent kinase 9 (CDK9). CDK9 is the catalytic subunit of the positive transcription elongation factor b (P-TEFb) complex, which plays a critical role in regulating gene transcription by phosphorylating the C-terminal domain of RNA polymerase II. In various cancer models, including multiple myeloma, osteosarcoma, and ovarian cancer, CDK9 siRNA is used to investigate the dependency of tumor cells on CDK9-mediated transcription of oncogenic survival factors like Mcl-1 and c-Myc. By knocking down CDK9, researchers can induce apoptosis and inhibit cell proliferation, validating CDK9 as a therapeutic target. It is primarily used as a laboratory tool and is not currently a clinical-stage therapeutic asset.
- Other names
- cyclin-dependent kinase 9 siRNAsiRNA-mediated CDK9 silencing reagent
02
Targets
CDK9 (Cyclin-dependent kinase 9)
Beyond the preview
Go deeper on CDK9 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK9 siRNA.